Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00481273 · ClinicalTrials.gov registry record
AVIDA The Vidaza® (Azacitidine) Patient Registry
A clinical trial, sponsored by Celgene.
- Completed
- Registry status
- 479
- Enrollment target
NCT00481273: Completed study, sponsored by Celgene.
NCT00481273 is a clinical trial that has completed, run by Celgene. The registered enrollment target is 479 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00481273 has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- 479 participants
- Enrollment target
Study Summary
This registry is a prospective, multi-center, observational study compiling data on the natural history and management of patients receiving Vidaza, and will provide unique insights into the management of myelodysplastic syndromes (MDS) and other hematological disorders and the impact of these disorders on patients.
Primary Outcome
Describe current usage patterns for Vidaza in the community
Interventions
- DRUG Azacitidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 479 participants |
| Start Date | 2006-10-31 |
| Est. Completion | 2010-08-31 |
What the finished NCT00481273 record still lists
NCT00481273 is an observational study that tracks outcomes without assigning an intervention. The registered 479 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Azacitidine is the first listed.
NCT00481273 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00481273 about?
NCT00481273 is a clinical study titled "AVIDA The Vidaza® (Azacitidine) Patient Registry". This registry is a prospective, multi-center, observational study compiling data on the natural history and management of patients receiving Vidaza, and will provide unique insights into the management of myelodysplastic syndromes (MDS) and other hematological disorders and the impact of these disor...
What is the current status of trial NCT00481273?
This trial is currently completed. The enrollment target is 479 participants. The study started on 2006-10-31. Estimated completion is 2010-08-31.
What interventions are being tested in trial NCT00481273?
The interventions under investigation include: Azacitidine (DRUG).
Who is sponsoring clinical trial NCT00481273?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04221542 · 479 participants · Phase 1
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
- NCT04948060 · 480 participants · NA
Tribally Engaged Approaches to Lung Screening (TEALS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI